Nikhita H. Poole

When, Where, and How Much: Toward Smarter Design and Delivery of CAR T-Cell Therapy

Abstract Chimeric antigen receptor (CAR) T-cell therapies have fundamentally reshaped clinical oncology by achieving durable remissions in refractory hematologic malignancies. However, their broader translation remains bottlenecked by severe, treatment-associated hyperinflammator...